Literature DB >> 94619

Electrophysiological study of human ventricular heart muscle treated with quinidine: interaction with isoprenaline.

H Nawrath, L Eckel.   

Abstract

We have investigated the effects of quinidine on the force of contraction and the intracellularly recorded action potential in papillary muscles isolated from human hearts. All preparations were obtained from patients undergoing corrective open heart surgery. The following results were obtained: (1) quinidine had a depressant effect on myocardial contractile force; (2) quinidine reduced the maximal upstroke velocity of the action potential; (3) quinidine shortened the plateau phase and prolonged the terminal repolarization of the action potential; (4) at higher concentrations quinidine reduced the resting potential; and (5) the depression by quinidine of both the plateau and the force of contraction was antagonized by isoprenaline. It is concluded that quinidine reduces the membrane conductances for sodium, calcium, and potassium ions. All of these actions of quinidine may contribute to the antiarrhythmic effects of the drug. The negative inotropic effect of quinidine can be explained by a depression of the calcium conductance at the myocardial cell membrane. The results show that earlier findings in laboratory animals regarding the effects of quinidine on the upstroke velocity and repolarization phase of the action potential are applicable to the human heart.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 94619     DOI: 10.1097/00005344-197907000-00004

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

1.  Human ex-vivo action potential model for pro-arrhythmia risk assessment.

Authors:  Guy Page; Phachareeya Ratchada; Yannick Miron; Guido Steiner; Andre Ghetti; Paul E Miller; Jack A Reynolds; Ken Wang; Andrea Greiter-Wilke; Liudmila Polonchuk; Martin Traebert; Gary A Gintant; Najah Abi-Gerges
Journal:  J Pharmacol Toxicol Methods       Date:  2016-05-25       Impact factor: 1.950

2.  Frequency-dependent effects of E-4031, almokalant, dofetilide and tedisamil on action potential duration: no evidence for "reverse use dependent" block.

Authors:  A Ohler; G J Amos; E Wettwer; U Ravens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-06       Impact factor: 3.000

3.  Antimuscarinic action of quinidine on the heart? A study in myocardial preparations from cat hearts.

Authors:  H Nawrath; U Sack; X Zong
Journal:  Br J Pharmacol       Date:  1984-01       Impact factor: 8.739

4.  Inotropic and electrophysiological effects of histamine on human ventricular heart muscle.

Authors:  L Eckel; R W Gristwood; H Nawrath; D A Owen; P Satter
Journal:  J Physiol       Date:  1982-09       Impact factor: 5.182

5.  Electrophysiological and other effects on rabbit hearts of CCI22277, a new steroidal antiarrhythmic drug.

Authors:  T J Campbell; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1982-06       Impact factor: 8.739

6.  A comparison of the effects of bethanidine, meobentine and quinidine on the electrical activity of rat hearts in vivo and in vitro.

Authors:  B J Northover
Journal:  Br J Pharmacol       Date:  1985-03       Impact factor: 8.739

7.  Differential effects of quinidine and flecainide on plateau duration of human atrial action potential.

Authors:  S Hatem; B Le Grand; J Y Le Heuzey; J P Couétil; E Deroubaix
Journal:  Basic Res Cardiol       Date:  1992 Nov-Dec       Impact factor: 17.165

8.  Differing electrophysiological effects of class IA, IB and IC antiarrhythmic drugs on guinea-pig sinoatrial node.

Authors:  T Campbell
Journal:  Br J Pharmacol       Date:  1987-06       Impact factor: 8.739

9.  Adult Human Primary Cardiomyocyte-Based Model for the Simultaneous Prediction of Drug-Induced Inotropic and Pro-arrhythmia Risk.

Authors:  Nathalie Nguyen; William Nguyen; Brynna Nguyenton; Phachareeya Ratchada; Guy Page; Paul E Miller; Andre Ghetti; Najah Abi-Gerges
Journal:  Front Physiol       Date:  2017-12-19       Impact factor: 4.566

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.